MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development
Funding will support a planned Phase III U.S. clinical trial in 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, today announced that its…